We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Tool Detects Most Common Bacterial Pathogens

By LabMedica International staff writers
Posted on 17 Dec 2014
Print article
Image: The workflow of the Prove-it Bone&Joint novel microarray-based assay (Photo courtesy of Mobidiag).
Image: The workflow of the Prove-it Bone&Joint novel microarray-based assay (Photo courtesy of Mobidiag).
A novel microarray-based assay was developed to detect over 60 of the most common Gram-positive and Gram-negative bacterial species including detection of mecA, vanA and vanB resistance genes directly from osteoarticular samples.

An assessment has been made of the performance of the diagnostic platform on primarily culture positive samples by comparing its results to bacterial culture and an in-house broad-range bacterial polymerase chain reaction (PCR). The extensive evaluation included not only samples of osteoarticular origin but also samples from other primary sterile body sites.

Clinical microbiologists at the University Hospital Basel (Switzerland) collected clinical samples from January to May 2012 from in-patients. Out of 200 samples, 120 were obtained from the osteoarticular apparatus (65 biopsies, 42 implants, and 13 aspirates), and 80 other samples from body sites like pleura, ascites, cerebrospinal fluid (CSF), lung, pancreas, gallbladder, heart valve as well as intracardial or breast prosthetic devices (40 biopsies, 27 aspirates, 6 implants, 5 CSF samples, and 2 others).

Aerobic and anaerobic bacterial cultures were carried out following standard protocols including enrichment culture using thioglycolate medium. Broad-range bacterial PCR was performed and samples producing visible PCR products were sequenced on the ABI 3130 Capillary Sequencer (Applied Biosystems; Foster City, USA). DNA extracts were tested with the Prove-it Bone&Joint Assay (Mobidiag; Helsinki, Finland).

In 129/176 (73.3%) one microorganism was isolated, monomicrobial samples, and in 47/176 (26.7%) more than one microorganism were isolated, polymicrobial samples. The sensitivity of Prove-it Bone&Joint assay in monomicrobial osteoarticular samples was 62.6% and in non-osteoarticular, it was 52.2%. When only samples containing species covered by the panel were included in the calculation, the sensitivities of both sample types were 72.2% and 68.6%, respectively. The Prove-it assay correctly predicted methicillin resistance/susceptibility in all 66 samples where phenotypical susceptibility testing was performed. In two samples, a positive signal for Staphylococcus aureus and mecA gene was detected. One sample contained a true methicillin-resistant S. aureus (MRSA) strain, while the other sample contained methicillin-sensitive S. aureus and methicillin-resistant Staphylococcus epidermidis.

The authors concluded that concluded that the Prove-it Bone&Joint assay is a highly rapid diagnostic tool providing early information on the identity of the most common pathogens present not only in osteoarticular but also in other primary sterile samples while awaiting definitive results of the culture. Although this assay can only detect a limited number of bacterial species present in the Prove-it panel, it may serve as an alternative for broad-range bacterial PCR in laboratories that are not capable of performing this sequence-based molecular analysis. The study was published in the December 2014 issue of the Journal of Microbiological Methods.

Related Links:

University Hospital Basel
Applied Biosystems 
Mobidiag


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.